PTC Therapeutics
PTCTPTC Therapeutics is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.In September 2009, PTC entered into an agreement with R …
© Wikipedia /
Creative Commons CC-BY-SA 3.0 more at Wikipedia
Insider trades and stock quote 2024-2026
All insider trades at PTC Therapeutics
Subscribe RSS| Date | Type | Insider | Position | Ø-Price | Volume |
|---|---|---|---|---|---|
| 5/15/2026 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $72.4 | $202,958 |
| 5/14/2026 | Sell | Klein, Matthew B. | CHIEF EXECUTIVE OFFICER | $72.9 | $917,154 |
| 5/8/2026 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $78.7 | $279,570 |
| 4/21/2026 | Sell | Klein, Matthew B. | CHIEF EXECUTIVE OFFICER | $70.9 | $202,094 |
| 4/6/2026 | Sell | Boulding, Mark Elliott | EXEC. VP AND CLO | $69.3 | $157,293 |
All information without guarantee! No recommendation/consultation!
© U.S. Securities and Exchange Commission (SEC)